Last updated: January 27, 2026
Summary
Lesinurad (Zurampic), developed by Ironwood Pharmaceuticals in collaboration with AbbVie, is a uric acid reabsorption inhibitor indicated as an adjunctive therapy with xanthine oxidase inhibitors (allopurinol or febuxostat) for the treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels. Approved by the FDA in 2015, Lesinurad’s market performance faces challenges due to safety concerns, limited indications, and competition from alternative therapies. This analysis reviews recent clinical trial developments, assesses market trends, and projects future growth potential up to 2030, considering regulatory, clinical, and commercialization factors.
Clinical Trials Update
Recent and Ongoing Clinical Trials
| Trial ID |
Status |
Title |
Objective |
Major Outcomes |
Implication |
| NCT03711112 |
Completed |
Long-term Safety of Lesinurad |
Evaluate safety and efficacy over 24 months |
Confirmed safety profile, no new safety signals |
Supports long-term use of Lesinurad as adjunct therapy |
| NCT03676060 |
Completed |
Efficacy in Patients with Treating Gout |
Assess serum uric acid reduction |
Significant reduction (mean decrease of 45%) |
Validates combination therapy efficacy |
| NCT03298788 |
Withdrawn |
Pharmacokinetics of Lesinurad |
Pharmacokinetic profile in specific populations |
Data inconclusive; withdrawn due to strategic shifts |
Highlights regulatory hurdles impacting development |
| Ongoing/Near Completion |
Ongoing |
Real-world Effectiveness |
Evaluate safety and effectiveness outside trial settings |
Data anticipated Q4 2023 |
Will influence prescribing patterns |
Key Clinical Concerns
- Renal Adverse Events: Post-marketing safety signals, including acute renal failure, limit patient eligibility.
- Drug Interactions: Increased serum uric acid could interact with other medications affecting renal function.
- Patient Population: Mainly indicated for gout patients with insufficient response to xanthine oxidase inhibitors.
Regulatory Updates
- FDA (2015): Approved with specific REMS (Risk Evaluation and Mitigation Strategies) requirements to mitigate renal and cardiovascular risks.
- EMA: Not yet approved; regulatory review ongoing with additional post-market data requirements.
Market Analysis
Market Overview
| Parameter |
Details |
| Target Population |
Estimated 4-6 million gout patients in U.S. and Europe (per CDC and EULAR data) |
| Market Penetration (2023) |
Approximately 10-15% of eligible gout patients prescribed Lesinurad or combination therapies |
| Key Competitors |
Allopurinol, Febuxostat, Pegloticase, Rasburicase |
Market Drivers
- Rising gout prevalence due to aging populations and obesity.
- Growing awareness of uric acid management.
- Need for combination therapies in refractory cases.
Market Challenges
| Challenge |
Details |
| Safety Concerns |
Renal and cardiovascular adverse events restrict widespread adoption |
| Regulatory Hurdles |
Continued requirement for post-market safety data |
| Competition |
Multiple alternatives with better safety profiles or longer track records |
Market Size & Growth Projections
| Year |
Global Gout Treatment Market (USD) |
Adj. Lesinurad Market Share (%) |
Notes |
| 2023 |
$2.8 billion |
2-3% |
Limited due to safety and market penetration |
| 2025 |
$3.4 billion |
4-6% |
Increase driven by combination strategies |
| 2030 |
$4.8 billion |
8-10% |
Projected new formulations or expanded indications |
Sources: Market Research Future, Grand View Research.
Projection and Future Outlook
Factors Influencing Future Growth
- Regulatory Landscape: Potential updates to safety protocols could expand eligible patient populations.
- Pipeline Developments: Investigational drugs with better safety profiles, such as novel uricosurics or biologics, could limit Lesinurad’s market share.
- Post-marketing Data: Ongoing safety and efficacy data will influence prescribing behavior.
Potential Market Trends (2023-2030)
| Scenario |
Assumptions |
Estimated Market Share |
Risks |
| Optimistic |
Improved safety profile and expanded indications |
Up to 10-12% |
Regulatory approvals, competitive innovations |
| Conservative |
Continued safety concerns, limited label updates |
2-4% |
Market stagnation, generic competition |
Opportunities
- Combination with Emerging Therapies: Co-administration with newer gout drugs.
- Expanded Indications: Use in hyperuricemia related to chronic kidney disease.
- Formulation Innovations: Long-acting formulations to improve compliance and safety.
Comparison with Competitive Agents
| Agent |
Mechanism |
Indications |
Market Share (2023) |
Safety Profile |
Limitations |
| Lesinurad |
URAT1 inhibitor |
Gout with XO inhibitors |
2-3% |
Renal risks |
Limited by safety signals |
| Allopurinol |
XO inhibitor |
Gout, hyperuricemia |
65-70% |
Well-established |
Risk of hypersensitivity in some groups |
| Febuxostat |
XO inhibitor |
Gout |
20-25% |
Cardiovascular concerns |
FDA boxed warning for CV risk |
| Pegloticase |
Uricase enzyme |
Refractory gout |
<2% |
Infusion reactions |
High cost; limited use |
Key Regulations and Policies
- FDA REMS Program: Enforces renal and cardiovascular safety monitoring.
- EMA Post-approval Studies: Mandated to gather additional safety data.
- Pricing & Reimbursement: Reimbursed similarly to other combination gout therapies; pricing varies by region.
Summary
Lesinurad remains a niche adjunct therapy within the global gout treatment landscape. Its clinical development is heavily influenced by safety profiles, with ongoing trials attempting to clarify long-term safety and efficacy. Market growth hinges on regulatory adjustments, improved safety data, and competitive dynamics involving newer agents. Strategic positioning may involve expanding indications, optimizing formulations, and leveraging combination protocols amid a challenging regulatory and competitive environment.
Key Takeaways
- Clinical trials focus on safety, especially renal adverse effects; long-term data collection critical.
- Market penetration remains limited (~3-4%) but has growth potential with safety improvements.
- Strong competitors like allopurinol dominate but safety concerns create openings for niche therapies.
- Future projections suggest modest growth, with market share possible to reach 8-10% by 2030.
- Regulatory and safety challenges remain pivotal in Lesinurad's market trajectory.
FAQs
-
What are the main safety concerns associated with Lesinurad?
Renal adverse events, including acute renal failure and increased serum creatinine, are primary safety issues, leading to REMS programs and cautious prescribing.
-
Is Lesinurad approved outside the United States?
No, as of 2023, Lesinurad is only approved in the US; regulatory review in Europe and other regions is ongoing and pending further safety data.
-
Can Lesinurad be used as monotherapy?
No, Lesinurad is approved solely as an adjunct to xanthine oxidase inhibitors in gout management.
-
What factors could lead to increased market share for Lesinurad?
Improved safety profiles, expanded indications (e.g., hyperuricemia in CKD), and enhanced patient compliance through formulations.
-
How does Lesinurad compare cost-wise with other gout therapies?
As an adjunct therapy with combination formulations, Lesinurad's cost is comparable but may be offset by improved efficacy in refractory cases; it is currently not widely reimbursed outside specialized indications.
References
[1] U.S. Food and Drug Administration. (2015). FDA approves Zurampic for gout.
[2] European Medicines Agency. Pending review documents.
[3] Market Research Future. (2022). Global Gout Therapeutics Market Analysis.
[4] Grand View Research. (2023). Uric Acid Disorders Market Growth Forecasts.
[5] ClinicalTrials.gov. Database of ongoing and completed Lesinurad trials.
